Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

196 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome.
Frére C, Cuisset T, Gaborit B, Alessi MC, Hulot JS. Frére C, et al. J Thromb Haemost. 2009 Aug;7(8):1409-11. doi: 10.1111/j.1538-7836.2009.03500.x. Epub 2009 May 30. J Thromb Haemost. 2009. PMID: 19496924 No abstract available.
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.
Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium. Scott SA, et al. Clin Pharmacol Ther. 2011 Aug;90(2):328-32. doi: 10.1038/clpt.2011.132. Epub 2011 Jun 29. Clin Pharmacol Ther. 2011. PMID: 21716271 Free PMC article. Review.
Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects.
Hulot JS, Wuerzner G, Bachelot-Loza C, Azizi M, Blanchard A, Peyrard S, Funck-Brentano C, Gaussem P. Hulot JS, et al. J Thromb Haemost. 2010 Mar;8(3):610-3. doi: 10.1111/j.1538-7836.2009.03729.x. Epub 2009 Dec 21. J Thromb Haemost. 2010. PMID: 20040040 Clinical Trial. No abstract available.
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.
Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium. Scott SA, et al. Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22. Clin Pharmacol Ther. 2013. PMID: 23698643 Free PMC article.
Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity.
Scott SA, Collet JP, Baber U, Yang Y, Peter I, Linderman M, Sload J, Qiao W, Kini AS, Sharma SK, Desnick RJ, Fuster V, Hajjar RJ, Montalescot G, Hulot JS. Scott SA, et al. Clin Pharmacol Ther. 2016 Sep;100(3):287-94. doi: 10.1002/cpt.401. Epub 2016 Jun 20. Clin Pharmacol Ther. 2016. PMID: 27213804 Free PMC article.
Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes.
Martis S, Peter I, Hulot JS, Kornreich R, Desnick RJ, Scott SA. Martis S, et al. Pharmacogenomics J. 2013 Aug;13(4):369-77. doi: 10.1038/tpj.2012.10. Epub 2012 Apr 10. Pharmacogenomics J. 2013. PMID: 22491019 Free PMC article.
The CLIPMERGE PGx Program: clinical implementation of personalized medicine through electronic health records and genomics-pharmacogenomics.
Gottesman O, Scott SA, Ellis SB, Overby CL, Ludtke A, Hulot JS, Hall J, Chatani K, Myers K, Kannry JL, Bottinger EP. Gottesman O, et al. Clin Pharmacol Ther. 2013 Aug;94(2):214-7. doi: 10.1038/clpt.2013.72. Epub 2013 Apr 3. Clin Pharmacol Ther. 2013. PMID: 23588317 Free PMC article. No abstract available.
Beta-blocker treatment in heart failure.
Bouzamondo A, Hulot JS, Sanchez P, Cucherat M, Lechat P. Bouzamondo A, et al. Fundam Clin Pharmacol. 2001 Apr;15(2):95-109. doi: 10.1046/j.1472-8206.2001.00019.x. Fundam Clin Pharmacol. 2001. PMID: 11468019 Review.
Sarcoplasmic reticulum and calcium cycling targeting by gene therapy.
Hulot JS, Senyei G, Hajjar RJ. Hulot JS, et al. Gene Ther. 2012 Jun;19(6):596-9. doi: 10.1038/gt.2012.34. Epub 2012 May 17. Gene Ther. 2012. PMID: 22673498 Review.
196 results
Jump to page
Feedback